Helsinn Hlthcare Drug Patent Portfolio
Helsinn Hlthcare owns 3 orange book drugs protected by 54 US patents Given below is the list of Helsinn Hlthcare's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10624911 | Physiologically balanced injectable formulations of fosnetupitant | 02 Jun, 2037 | Active |
| US11529362 | Physiologically balanced injectable formulations of fosnetupitant | 02 Jun, 2037 | Active |
| US10233154 | Crystalline forms of an NK-1 antagonist | 25 Sep, 2035 | Active |
| US10676440 | Crystalline forms of an NK-1 antagonist | 25 Sep, 2035 | Active |
| US10961195 | Crystalline forms of an NK-1 antagonist | 25 Sep, 2035 | Active |
| US9951016 | Crystalline forms of an NK-1 antagonist | 25 Sep, 2035 | Active |
| US10278969 | Pharmaceutical dosage forms | 11 Dec, 2034 | Active |
| US11160804 | Pharmaceutical dosage forms | 11 Dec, 2034 | Active |
| US10208073 | Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator | 23 May, 2032 | Active |
| US10717721 | Substituted piperaziniums for the treatment of emesis | 23 May, 2032 | Active |
| US11312698 | Fosnetupitant chloride hydrochloride having improved stability | 23 May, 2032 | Active |
| US8426450 | Substituted 4-phenyl pyridines having anti-emetic effect | 23 May, 2032 | Active |
| US8895586 | Methods of treating emesis | 23 May, 2032 | Active |
| US9403772 | 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator | 23 May, 2032 | Active |
| US9908907 | Substituted piperaziniums for the treatment of emesis | 23 May, 2032 | Active |
| US9271975 | Compositions and methods for treating centrally mediated nausea and vomiting | 09 Sep, 2031 | Active |
| US10828297 | Compositions and methods for treating centrally mediated nausea and vomiting | 17 Dec, 2030 | Active |
| US11559523 | Compositions and methods for treating centrally mediated nausea and vomiting | 18 Nov, 2030 | Active |
| US12042494 | Compositions and methods for treating centrally mediated nausea and vomiting | 18 Nov, 2030 | Active |
| US8623826 | Compositions and methods for treating centrally mediated nausea and vomiting | 18 Nov, 2030 | Active |
| US8951969 | Compositions and methods for treating centrally mediated nausea and vomiting | 18 Nov, 2030 | Active |
| US9186357 | Compositions and methods for treating centrally mediated nausea and vomiting | 18 Nov, 2030 | Active |
| US9943515 | Compositions and methods for treating centrally mediated nausea and vomiting | 18 Nov, 2030 | Active |
| US8552002 | Compounds and compositions as protein kinase inhibitors | 25 Aug, 2029 | Active |
| US9067896 | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof | 06 Aug, 2028 | Active |
| US7947724 | Liquid pharmaceutical formulations of palonosetron | 30 Jul, 2024 | Expired |
| US7947725 | Liquid pharmaceutical formulations of palonosetron | 30 Jul, 2024 | Expired |
| US7960424 | Liquid pharmaceutical formulations of palonosetron | 30 Jul, 2024 | Expired |
| US8518981 | Liquid pharmaceutical formulations of palonosetron | 30 Jul, 2024 | Expired |
| US8598218 | Liquid pharmaceutical formulations of palonosetron | 30 Jul, 2024 | Expired |
| US8598219 | Liquid pharmaceutical formulations of palonosetron | 30 Jul, 2024 | Expired |
| US8729094 | Liquid pharmaceutical formulations of palonosetron | 30 Jul, 2024 | Expired |
| US9066980 | Liquid pharmaceutical formulations of palonosetron | 30 Jul, 2024 | Expired |
| US9125905 | Liquid pharmaceutical formulations of palonosetron | 30 Jul, 2024 | Expired |
| US9173942 | Liquid pharmaceutical formulations of palonosetron | 30 Jul, 2024 | Expired |
| US9439854 | Liquid pharmaceutical formulations of palonosetron | 30 Jul, 2024 | Expired |
| US9457020 | Liquid pharmaceutical formulations of palonosetron | 30 Jul, 2024 | Expired |
| US9457021 | Liquid pharmaceutical formulations of palonosetron | 30 Jul, 2024 | Expired |
| US7947724 | Liquid pharmaceutical formulations of palonosetron | 30 Jan, 2024 | Expired |
| US7947725 | Liquid pharmaceutical formulations of palonosetron | 30 Jan, 2024 | Expired |
| US7960424 | Liquid pharmaceutical formulations of palonosetron | 30 Jan, 2024 | Expired |
| US8518981 | Liquid pharmaceutical formulations of palonosetron | 30 Jan, 2024 | Expired |
| US8598218 | Liquid pharmaceutical formulations of palonosetron | 30 Jan, 2024 | Expired |
| US8598219 | Liquid pharmaceutical formulations of palonosetron | 30 Jan, 2024 | Expired |
| US8729094 | Liquid pharmaceutical formulations of palonosetron | 30 Jan, 2024 | Expired |
| US9066980 | Liquid pharmaceutical formulations of palonosetron | 30 Jan, 2024 | Expired |
| US9125905 | Liquid pharmaceutical formulations of palonosetron | 30 Jan, 2024 | Expired |
| US9173942 | Liquid pharmaceutical formulations of palonosetron | 30 Jan, 2024 | Expired |
| US9439854 | Liquid pharmaceutical formulations of palonosetron | 30 Jan, 2024 | Expired |
| US9457020 | Liquid pharmaceutical formulations of palonosetron | 30 Jan, 2024 | Expired |
| US9457021 | Liquid pharmaceutical formulations of palonosetron | 30 Jan, 2024 | Expired |
| US6297375 | 4-phenyl-pyridine derivatives | 17 Mar, 2023 | Expired |
| US5202333 | Tricyclic 5-HT3 receptor antagonists | 13 Oct, 2015 | Expired |
| US5202333 | Tricyclic 5-HT3 receptor antagonists | 13 Apr, 2015 | Expired |
Latest Legal Activities on Helsinn Hlthcare's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Helsinn Hlthcare.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 27 May, 2024 | US9457020 |
| Miscellaneous Incoming Letter | 23 May, 2024 | US8552002 |
| Letter from FDA or Dept of Agriculture re PTE application | 16 May, 2024 | US8552002 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 18 Apr, 2024 | US10828297 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 24 Jan, 2024 | US9403772 |
| transaction for FDA Determination of Regulatory Review Period | 18 Jan, 2024 | US8552002 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Dec, 2023 | US10717721 |
| transaction for FDA Determination of Regulatory Review Period | 07 Dec, 2023 | US8552002 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Nov, 2023 | US10676440 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Sep, 2023 | US10624911 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Aug, 2023 | US9271975 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Apr, 2023 | US9186357 |
| Second letter to regulating agency to determine regulatory review period | 09 Mar, 2023 | US8552002 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Feb, 2023 | US9125905 (Litigated) |
|
Recordation of Patent Grant Mailed
Critical
| 24 Jan, 2023 | US11559523 |
Helsinn Hlthcare's Drug Patent Litigations
Helsinn Hlthcare's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Sep 02, 2014, against patent number US8598219. The petitioner Accord Healthcare, Inc., challenged the validity of this patent, with Helsinn Healthcare S.A. as the respondent. Click below to track the latest information on how companies are challenging Helsinn Hlthcare's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9173942 | February, 2016 |
Terminated-Denied
(17 Aug, 2016)
| Helsinn Healthcare S.A. | Dr. Reddy's Laboratories, Ltd |
| US8729094 | July, 2015 |
Terminated-Denied
(14 Oct, 2015)
| Helsinn Healthcare S.A. | Dr. Reddy's Laboratories, Ltd |
| US8729094 | July, 2015 |
Terminated-Denied
(14 Oct, 2015)
| Helsinn Healthcare S.A. | Dr. Reddy's Laboratories, Ltd. |
| US8598219 | September, 2014 |
Terminated-Denied
(24 Nov, 2014)
| Helsinn Healthcare S.A. | Accord Healthcare, Inc. |
Helsinn Hlthcare Drug Patents' Oppositions Filed in EPO
Helsinn Hlthcare drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 08, 2009, by Tecnimede Sociedade Tecnico-Medicinal, S.A.. This opposition was filed on patent number EP04706657A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP14151676A | Jul, 2016 | Teva Pharmaceutical Industries Ltd | Opposition rejected |
| EP04706657A | Jul, 2009 | DR REDDYS LABORATORIES (UK) LIMITED | Revoked |
| EP04706657A | Jul, 2009 | White, Martin Paul | Revoked |
| EP04706657A | Jul, 2009 | Tecnimede Sociedade Tecnico-Medicinal, S.A. | Revoked |
Helsinn Hlthcare's Family Patents
Helsinn Hlthcare drugs have patent protection in a total of 58 countries. It's US patent count contributes only to 16.6% of its total global patent coverage. 8 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Helsinn Hlthcare Drug List
Given below is the complete list of Helsinn Hlthcare's drugs and the patents protecting them.
1. Akynzeo
Akynzeo is protected by 23 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10624911 | Physiologically balanced injectable formulations of fosnetupitant |
02 Jun, 2037
(12 years from now)
| Active |
| US11529362 | Physiologically balanced injectable formulations of fosnetupitant |
02 Jun, 2037
(12 years from now)
| Active |
| US10233154 | Crystalline forms of an NK-1 antagonist |
25 Sep, 2035
(10 years from now)
| Active |
| US10676440 | Crystalline forms of an NK-1 antagonist |
25 Sep, 2035
(10 years from now)
| Active |
| US10961195 | Crystalline forms of an NK-1 antagonist |
25 Sep, 2035
(10 years from now)
| Active |
| US9951016 | Crystalline forms of an NK-1 antagonist |
25 Sep, 2035
(10 years from now)
| Active |
| US10208073 | Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator |
23 May, 2032
(7 years from now)
| Active |
| US10717721 | Substituted piperaziniums for the treatment of emesis |
23 May, 2032
(7 years from now)
| Active |
| US11312698 | Fosnetupitant chloride hydrochloride having improved stability |
23 May, 2032
(7 years from now)
| Active |
| US8426450 | Substituted 4-phenyl pyridines having anti-emetic effect |
23 May, 2032
(7 years from now)
| Active |
| US8895586 | Methods of treating emesis |
23 May, 2032
(7 years from now)
| Active |
| US9403772 | 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator |
23 May, 2032
(7 years from now)
| Active |
| US9908907 | Substituted piperaziniums for the treatment of emesis |
23 May, 2032
(7 years from now)
| Active |
| US9271975 | Compositions and methods for treating centrally mediated nausea and vomiting |
09 Sep, 2031
(6 years from now)
| Active |
| US10828297 | Compositions and methods for treating centrally mediated nausea and vomiting |
17 Dec, 2030
(6 years from now)
| Active |
| US11559523 | Compositions and methods for treating centrally mediated nausea and vomiting |
18 Nov, 2030
(6 years from now)
| Active |
| US12042494 | Compositions and methods for treating centrally mediated nausea and vomiting |
18 Nov, 2030
(6 years from now)
| Active |
| US8623826 | Compositions and methods for treating centrally mediated nausea and vomiting |
18 Nov, 2030
(6 years from now)
| Active |
| US8951969 | Compositions and methods for treating centrally mediated nausea and vomiting |
18 Nov, 2030
(6 years from now)
| Active |
| US9186357 | Compositions and methods for treating centrally mediated nausea and vomiting |
18 Nov, 2030
(6 years from now)
| Active |
| US9943515 | Compositions and methods for treating centrally mediated nausea and vomiting |
18 Nov, 2030
(6 years from now)
| Active |
| US6297375 | 4-phenyl-pyridine derivatives |
17 Mar, 2023
(1 year, 8 months ago)
| Expired |
| US5202333 | Tricyclic 5-HT3 receptor antagonists |
13 Apr, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Akynzeo's drug page
2. Aloxi
Aloxi is protected by 28 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7947724
(Pediatric)
| Liquid pharmaceutical formulations of palonosetron |
30 Jul, 2024
(3 months ago)
| Expired |
| US7947725
(Pediatric)
| Liquid pharmaceutical formulations of palonosetron |
30 Jul, 2024
(3 months ago)
| Expired |
| US7960424
(Pediatric)
| Liquid pharmaceutical formulations of palonosetron |
30 Jul, 2024
(3 months ago)
| Expired |
| US8518981
(Pediatric)
| Liquid pharmaceutical formulations of palonosetron |
30 Jul, 2024
(3 months ago)
| Expired |
| US8598218
(Pediatric)
| Liquid pharmaceutical formulations of palonosetron |
30 Jul, 2024
(3 months ago)
| Expired |
| US8598219
(Pediatric)
| Liquid pharmaceutical formulations of palonosetron |
30 Jul, 2024
(3 months ago)
| Expired |
| US8729094
(Pediatric)
| Liquid pharmaceutical formulations of palonosetron |
30 Jul, 2024
(3 months ago)
| Expired |
| US9066980
(Pediatric)
| Liquid pharmaceutical formulations of palonosetron |
30 Jul, 2024
(3 months ago)
| Expired |
| US9125905
(Pediatric)
| Liquid pharmaceutical formulations of palonosetron |
30 Jul, 2024
(3 months ago)
| Expired |
| US9173942
(Pediatric)
| Liquid pharmaceutical formulations of palonosetron |
30 Jul, 2024
(3 months ago)
| Expired |
| US9439854
(Pediatric)
| Liquid pharmaceutical formulations of palonosetron |
30 Jul, 2024
(3 months ago)
| Expired |
| US9457020
(Pediatric)
| Liquid pharmaceutical formulations of palonosetron |
30 Jul, 2024
(3 months ago)
| Expired |
| US9457021
(Pediatric)
| Liquid pharmaceutical formulations of palonosetron |
30 Jul, 2024
(3 months ago)
| Expired |
| US7947724 | Liquid pharmaceutical formulations of palonosetron |
30 Jan, 2024
(9 months ago)
| Expired |
| US7947725 | Liquid pharmaceutical formulations of palonosetron |
30 Jan, 2024
(9 months ago)
| Expired |
| US7960424 | Liquid pharmaceutical formulations of palonosetron |
30 Jan, 2024
(9 months ago)
| Expired |
| US8518981 | Liquid pharmaceutical formulations of palonosetron |
30 Jan, 2024
(9 months ago)
| Expired |
| US8598218 | Liquid pharmaceutical formulations of palonosetron |
30 Jan, 2024
(9 months ago)
| Expired |
| US8598219 | Liquid pharmaceutical formulations of palonosetron |
30 Jan, 2024
(9 months ago)
| Expired |
| US8729094 | Liquid pharmaceutical formulations of palonosetron |
30 Jan, 2024
(9 months ago)
| Expired |
| US9066980 | Liquid pharmaceutical formulations of palonosetron |
30 Jan, 2024
(9 months ago)
| Expired |
| US9125905 | Liquid pharmaceutical formulations of palonosetron |
30 Jan, 2024
(9 months ago)
| Expired |
| US9173942 | Liquid pharmaceutical formulations of palonosetron |
30 Jan, 2024
(9 months ago)
| Expired |
| US9439854 | Liquid pharmaceutical formulations of palonosetron |
30 Jan, 2024
(9 months ago)
| Expired |
| US9457020 | Liquid pharmaceutical formulations of palonosetron |
30 Jan, 2024
(9 months ago)
| Expired |
| US9457021 | Liquid pharmaceutical formulations of palonosetron |
30 Jan, 2024
(9 months ago)
| Expired |
| US5202333
(Pediatric)
| Tricyclic 5-HT3 receptor antagonists |
13 Oct, 2015
(9 years ago)
| Expired |
| US5202333 | Tricyclic 5-HT3 receptor antagonists |
13 Apr, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aloxi's drug page
3. Truseltiq
Truseltiq is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10278969 | Pharmaceutical dosage forms |
11 Dec, 2034
(10 years from now)
| Active |
| US11160804 | Pharmaceutical dosage forms |
11 Dec, 2034
(10 years from now)
| Active |
| US8552002 | Compounds and compositions as protein kinase inhibitors |
25 Aug, 2029
(4 years from now)
| Active |
| US9067896 | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof |
06 Aug, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Truseltiq's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List